Sarah Lynda Lakhdari

Leading medical team & strategy for cardiology and transplantation:

• Launch strategy of alirocumab in a matrix environment including tactical implementation , execution and accountability
• Lead clinical development and align the life cycle management (LCM )strategy to ensure high quality of scientific evidence (including RWE)

-French expert group proposal for lipid lowering therapy in the first 3 months after acute myocardial infarction:

-Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France

• Development of a highly engaged community of KOL's in optimising post acute coronary syndrome patients pathway and LDL-c management
• Establishment of innovative and highly differentiating partnerships by taking a multichannel metrics approach that included third party and key academic societies
• Driving transformation strategy and digital opinion leaders strategy while fostering holistic communication to create a virtuous cycle of gathering insights and adapting the strategy accordingly
• Core member of the global post acute coronary syndrome (ACS)pathway task force , which has amplified experts voices and co created valuable projects to improve post ACS patient pathway
• Lead of transplant portfolio and belumosudil compassionate use access forchronic graft vers host disease (cGVHD)patients

• Apply the 'Medical Launch Readiness' framework to pre-launch activities
• Enable cross-functional alignment with the relevant groups for pre-launch activities within Sanofi
• Identify high priority evidence gaps where evidence generation studies are needed

Business Drivers (and Course Impact)

• Accelerate the portfolio (faster and more value-added launch)
• Improve ways of working (higher retention and employee satisfaction)
• Create efficiencies (cost savings and cost avoidance)
• Accelerate the portfolio (faster and more value-added launch)
• Improve ways of working (higher retention and employee satisfaction)
• Create efficiencies (cost savings and cost avoidance)

• Successful implementation of three global forums hi lighting the essential role of RWE and contributing to a vibrant RWE community.
• Lead of the RWE Upskilling task force

• Leading the medical strategy and launch of alirocuamb , involving key experts and a communication plan relayed by academic societies s

• Leading the medical strategy to secure access and strengthen the place of enoxaparin in thrombosis
• Leading a strong scientific leadership relay on academic scientific societies: mapping & engagement of key experts
• Innovative communication plan including digital transformation: co-leader of the first European webinar organized during ISTH congress ( 21 countries worldwide ,> 1500 registrations, ~ 690 attendees during live session)
• Core member of the European working group for thrombosis

• Leading medical strategy and registration of blockboosters cardiology portfolio (Irbesartan- amlodipine..)
• Engagement of key advocacy and a high quality delivery of scientific evidence (observational studies - phase III program)

• Lead of diabetes medical strategy for the launch of blookboosters products (Lantus-Apidra )
• Designed local clinical trials and communication plan
• Build a strong scientific leadership relay on academic scientific societies and key experts
• Elaboration and implementation of Patient Support Programs (lawarded award-winning diabetes education programme at school)